Skip to main content
Clinical Trials/NCT00841256
NCT00841256
Completed
Phase 3

... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo

Allergopharma GmbH & Co. KG1 site in 1 country207 target enrollmentFebruary 2008

Overview

Phase
Phase 3
Intervention
Grass pollen allergens in a water/glycerol solution
Conditions
Allergic Rhinoconjunctivitis
Sponsor
Allergopharma GmbH & Co. KG
Enrollment
207
Locations
1
Primary Endpoint
Changes of Symptom-Medication-Score
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

Detailed Description

Although highly effective, subcutaneous administration of allergens may cause inconvenience in some patients. Alternative routes, e.g. nasal and oral, have therefore been investigated to find an immunotherapy regimen largely accepted by all groups of patients, including children. Sublingual specific immunotherapy (SLIT) may represent a more acceptable route of immunotherapy. It may be an optimal therapy option especially for children because they often fear injections. In this study children are to be treated with a preparation of a grass pollen allergen extract in a water/glycerol solution with phosphate buffered saline in comparison to a symptomatic standard treatment with add on placebo, in order to investigate efficacy and safety of the study drug.

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
August 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 4 - \<12 years (at the time of inclusion)
  • Positive SPT
  • Positive EAST
  • Positive CPT

Exclusion Criteria

  • Serious chronic diseases
  • Other perennial allergies

Arms & Interventions

Immunotherapy

Grass pollen allergens in a water/glycerol solution

Intervention: Grass pollen allergens in a water/glycerol solution

Placebo

Water/glycerol solution with phosphate buffered saline

Intervention: Placebo

Outcomes

Primary Outcomes

Changes of Symptom-Medication-Score

Time Frame: After 1 year of treatment

The change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.

Secondary Outcomes

  • Evaluation of the documentation of adverse events (AEs)(Entire treatment period)

Study Sites (1)

Loading locations...

Similar Trials